MarketPeel
Insider Trading Intelligence
AF

Alexander A. Fitzpatrick

SPRY
CHIEF LEGAL OFFICER · ARS PHARMACEUTICALS, INC. · CIK 0001398595
FILING MIX · LIFETIME70%/30%
BUYS
7
SELLS
3
TOTAL VALUE
$2.36M
COMPANIES
1
ACTIVE SINCE
Jan 2023
HOLDINGS NOW
90,910
AVG SELL PX
$13.97
TRADE KIND
SHOWING 10 / 10
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by Alexander A. Fitzpatrick, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+66.67%+8.10%-0.25%+8.35%+10.25%
14d3+33.33%+0.94%+0.90%+0.04%+0.85%
30d3+0.00%-0.61%-2.06%+1.44%-0.77%
60d3+66.67%+26.88%+6.11%+20.77%+20.96%
90d3+100.00%+33.79%+10.71%+23.08%+36.98%
180d3+100.00%+96.18%+19.16%+77.02%+140.23%
1y3+100.00%+173.97%+31.95%+142.01%+243.34%
2y3(1 pending)+100.00%+162.82%+57.94%+104.87%+104.87%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SPRY · 90,910 shares · as of Jun 12, 2026
0175,000350,000525,000700,000202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 7 buys / 3 sellsCOVERAGE · 14 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
3,355$10.00$33.5K90,910Jun 12, 2026Jun 12, 2026View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
240,000240,000Jan 2, 2026Jan 5, 2026View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Legal Officer
102,969$14.10$1.45M89,613May 20, 2025May 22, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Legal Officer
100,000200,000May 20, 2025May 22, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Legal Officer
100,000$5.58$558.0K192,582May 20, 2025May 22, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
152,300152,300Jan 2, 2025Jan 3, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
300,000300,000Jan 2, 2024Jan 4, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Legal Officer
46,258$3.78$175.0K89,227Sep 29, 2023Oct 2, 2023View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Legal Officer
40,000$3.62$145.0K42,969Sep 28, 2023Oct 2, 2023View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
700,000700,000Jan 3, 2023Jan 5, 2023View →
Other insiders · SPRY
Loading peer insiders…
About this filer
CIK 0001398595
ROLE
Chief Legal Officer
PRIMARY
SPRY
COMPANIES
1
ACTIVE SINCE
Jan 2023
MARKETPEEL · /INSIDER/0001398595DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback